Last reviewed · How we verify
NA-931 dose 3, daily and orally — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
NA-931 dose 3, daily and orally (NA-931 dose 3, daily and orally) — Biomed Industries, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NA-931 dose 3, daily and orally TARGET | NA-931 dose 3, daily and orally | Biomed Industries, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NA-931 dose 3, daily and orally CI watch — RSS
- NA-931 dose 3, daily and orally CI watch — Atom
- NA-931 dose 3, daily and orally CI watch — JSON
- NA-931 dose 3, daily and orally alone — RSS
Cite this brief
Drug Landscape (2026). NA-931 dose 3, daily and orally — Competitive Intelligence Brief. https://druglandscape.com/ci/na-931-dose-3-daily-and-orally. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab